Fresenius SE & Co KGaA (FRE.DE) Azione Prezzo
Fresenius SE & Co KGaA Prezzo
Il fatturato è cresciuto a un tasso composto del 4,0% annuo negli ultimi 19 anni, raggiungendo 22,87 miliardi EUR. L'utile per azione è cresciuto del 6,2% all'anno negli ultimi 19 anni. Il margine netto di Fresenius SE & Co KGaA si attesta al 5,5%, sostanzialmente stabile rispetto al 4,9% di alcuni anni fa. Fresenius SE & Co KGaA offre attualmente un rendimento da dividendo di circa il 2,15%. Il payout ratio è pari a circa il 45% degli utili. Il dividendo è cresciuto del 10,0% all'anno negli ultimi 19 anni. Gli analisti fissano un target di prezzo mediano di 57,12 EUR, ovvero il 23,1% sopra il prezzo attuale. Su 23 analisti, 21 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Fresenius SE & Co KGaA Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Fresenius SE & Co KGaA Azione e analisi azionaria
Domande frequenti sull'azione Fresenius SE & Co KGaA
Fresenius SE is a German healthcare company specializing in the provision of medical products and services. The company's business model focuses on four main segments: Fresenius Medical Care, a global leader in dialysis treatment and services; Fresenius Kabi, offering essential medicines and clinical nutrition products; Fresenius Helios, providing high-quality hospital and healthcare services; and Fresenius Vamed, specializing in projects and services for healthcare facilities. Through these segments, Fresenius SE aims to contribute to the improvement of patients' quality of life, offering comprehensive and innovative healthcare solutions worldwide.
Fresenius SE is primarily active in the healthcare industry.
The main competitors of Fresenius SE in the market include Baxter International Inc, DaVita Inc, and Cardinal Health Inc.
Fresenius SE is a prominent healthcare company with a rich history and background. Founded in 1912 by Dr. Eduard Fresenius, the company started as a pharmaceutical laboratory in Germany. Over the years, it expanded its services and is now a global leader in dialysis products, hospital equipment, and healthcare services. With a strong commitment to improve the quality of life for patients worldwide, Fresenius SE operates through its four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Its innovative technologies, extensive expertise, and global presence have propelled Fresenius SE to become a trusted name in the healthcare industry.
Fresenius SE, a leading healthcare company, has achieved several significant milestones throughout its history. It successfully expanded its global presence, delivering high-quality healthcare products and services to millions of patients worldwide. Fresenius SE also made notable advancements in the field of dialysis, offering innovative solutions for the treatment of chronic kidney failure. Moreover, the company has been at the forefront of pharmaceutical manufacturing and distribution, ensuring the availability of essential medications for various medical conditions. With a strong dedication to patient care and continuous innovation, Fresenius SE has consistently enhanced the quality of life for individuals around the globe.
Fresenius SE is primarily present in numerous countries and regions around the world. The company operates in various key markets, including Germany, North America, Europe, Latin America, Asia-Pacific, and Africa. With a global presence, Fresenius SE has established a strong foothold in these regions, allowing it to expand its reach and serve a diverse customer base. The company's commitment to delivering high-quality healthcare products and services has enabled it to successfully operate and thrive in these international markets.
Fresenius SE represents values of innovation, quality, and patient care in its corporate philosophy. As a leading healthcare company, Fresenius SE is committed to providing high-quality products and services for patients worldwide. It focuses on four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. These divisions serve different aspects of healthcare, such as dialysis, infusion therapy, hospital operations, and project development. With a strong emphasis on research and development, Fresenius SE constantly strives to improve medical treatments and enhance patient well-being. By upholding these values, Fresenius SE has become a trusted name in the healthcare industry.
Gli analisti fissano attualmente un prezzo obiettivo medio di 56,38 EUR per l’azione Fresenius SE & Co KGaA (mediana: 57,12 EUR), pari a +21,5 % rispetto all’ultimo prezzo. Il consenso si basa su 23 giudizi di analisti.
23 analisti valutano attualmente l’azione Fresenius SE & Co KGaA: 21 raccomandano l’acquisto, 2 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Fresenius SE & Co KGaA ricavi pari a 23,72 miliardi EUR e un utile per azione di 3,67 EUR.
L’azione Fresenius SE & Co KGaA (FRE.DE) è quotata su 10 borse, tra cui: London (0OO9.L), SIX (Zürich) (FREEUR.SW), XETRA (FRE.DE), Frankfurt (FRE.F), München (FRE.MU), Düsseldorf (FRE.DU), Hamburg (FRE.HM), Wien (FRE.VI).
Fresenius SE is a globally leading healthcare company based in Germany. The company consists of four main business segments, including Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care is the world's largest provider of dialysis products and services. Their portfolio includes dialysis machines, dialysis filters, and accessories, as well as innovative therapies such as hemodiafiltration and online hemodiafiltration. Additionally, Fresenius Medical Care offers comprehensive services for patients with chronic kidney diseases, including consultation, training, and support for better quality of life. Fresenius Kabi manufactures products for infusion and nutrition therapy and is a global market leader in this field. Their portfolio includes parenteral nutrition products, infusion solutions, pain therapeutics, and antibiotics. Furthermore, Fresenius Kabi provides intensified therapeutic care for patients to enable a quick recovery. Fresenius Helios is Europe's largest private hospital operator. The company operates over 100 acute clinics, rehabilitation clinics, and outpatient clinics in Germany and Spain, with a total of more than 100,000 beds. Fresenius Helios offers a wide range of medical services, including emergency care, oncology and neurology, cardiology, and orthopedics. Fresenius Vamed is an internationally active service provider for healthcare and social infrastructure. The company offers planning, construction, management, and optimization of healthcare facilities, as well as energy-efficient solutions for facility management. Fresenius Vamed also operates rehabilitation facilities, wellness facilities, and obesity centers. Fresenius SE was founded in 1912 and currently employs over 300,000 employees in over 100 countries. The company is headquartered in Bad Homburg vor der Höhe, Germany, and is listed on the Frankfurt Stock Exchange. Overall, Fresenius SE offers a wide range of products and services for all areas of healthcare, from dialysis and infusion therapy to hospital care and health infrastructure. The company is committed to improving the quality of life of their patients and ensuring high-quality medical care.
Il attesa fatturato di Fresenius SE & Co KGaA ammonta a 23,72 miliardi EUR. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Fresenius SE & Co KGaA ammonta a 2,07 miliardi EUR. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Fresenius SE & Co KGaA è attualmente 12,66. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Fresenius SE & Co KGaA.
Il rapporto prezzo/fatturato (P/S) di Fresenius SE & Co KGaA è attualmente 1,10. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Fresenius SE & Co KGaA.
Il Quality Score AlleAktien per Fresenius SE & Co KGaA è 3/10.
L'ISIN di Fresenius SE & Co KGaA è DE0005785604. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Fresenius SE & Co KGaA è 578560. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Fresenius SE & Co KGaA è FRE.DE. Con questo simbolo di borsa vengono negoziate le azioni Fresenius SE & Co KGaA in borsa.
Azione Fresenius SE & Co KGaA
Gruppo di pari di Fresenius SE & Co KGaA
Fresenius SE & Co KGaA Ticker
Fresenius SE & Co KGaA FIGI
Altre metriche e analisi di Fresenius SE & Co KGaA in Deep Dive.
La nostra analisi azionaria dell'azione Fresenius SE & Co KGaA include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Fresenius SE & Co KGaA. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: